Artane is intended for people with selected Parkinson’s disease symptoms and movement disorders. Its anticholinergic action can help control muscle stiffness, tremor, and some involuntary movements, while requiring regular review of cognitive and physical effects.
Artane tablets contain trihexyphenidyl, an anticholinergic used for selected Parkinson’s disease symptoms and movement disorders. It can reduce muscle stiffness, tremor, and some involuntary movements by altering acetylcholine signalling in the brain. Careful dose adjustment is needed because the same action may affect memory, vision, urination, and concentration.
The active ingredient is trihexyphenidyl. It belongs to the centrally acting anticholinergic class, which reduces the effect of acetylcholine, a neurotransmitter involved in nerve signalling and muscle control.
Artane is supplied as tablets. The prescribed dose is decided individually, taking age, other medicines, and health conditions into account.
Artane is prescribed when reducing cholinergic activity may improve selected movement symptoms. Its main therapeutic role is symptom control; it does not reverse the underlying neurological changes of Parkinson’s disease.
A clinician may prescribe Artane for symptoms such as:
Artane may be used alone or alongside other treatment, depending on the person’s symptoms and response. It is not suitable for every type of tremor, and a new or worsening movement problem needs clinical assessment before treatment is started or changed.
Trihexyphenidyl may be considered for selected movement disorders when an anticholinergic effect is clinically appropriate. Use outside the main licensed indication requires a specific assessment of the diagnosis, expected benefit, age, cognition, bladder function, and other medicines.
The benefit should be judged against practical effects such as dry mouth, constipation, blurred vision, drowsiness, and reduced concentration.
Trihexyphenidyl dosing is individualised and commonly adjusted gradually. The aim is to balance movement control with anticholinergic adverse effects.
The dose is decided individually, taking age, other medicines, and health conditions into account. A prescriber may adjust the dose according to:
Do not start, stop, or change Artane independently. Abrupt changes can make symptom control less predictable and may complicate assessment of whether the treatment is helping.
Take Artane tablets at the prescribed times and keep the daily schedule consistent. If a dose is missed, the usual approach is to take it when remembered unless the next scheduled dose is near; a missed dose should not automatically be doubled.
The exact action depends on the prescribed schedule and the time elapsed. A New Zealand pharmacist or prescriber can give patient-specific instructions using the actual dosing plan.
Artane may be unsuitable or require special supervision in people with:
The most relevant interaction pattern is additive anticholinergic activity, which can increase dry mouth, constipation, blurred vision, urinary difficulty, drowsiness, and confusion.
This medication is not for you if a prescriber has identified a contraindication such as angle-closure glaucoma, urinary retention, or a serious bowel obstruction. Those conditions can worsen when anticholinergic activity is increased.
Tell the prescriber about every prescription medicine, over-the-counter product, and supplement. Alcohol may worsen drowsiness, dizziness, impaired concentration, and poor coordination. Driving, cycling, and operating machinery require caution until the individual response is clear.
Artane can cause anticholinergic adverse effects because acetylcholine is involved in several body systems. The risk may increase with higher doses, older age, dehydration, kidney or liver problems, and other medicines with similar activity.
Possible effects include:
Sugar-free gum or frequent small sips of water may ease mild dry mouth when fluid restriction is not required for another condition. Persistent constipation needs attention because untreated symptoms can become severe.
Dry mouth can also hide dehydration. A person may drink less because swallowing feels uncomfortable, then become dizzy or overheated.
Artane can cause memory problems, reduced concentration, confusion, agitation, or hallucinations. These effects deserve extra attention in older adults and in people with existing cognitive impairment.
Family members may notice unusual behaviour before the person taking the tablets recognises a change. New confusion, marked drowsiness, hallucinations, or sudden agitation should prompt a call to the prescriber rather than an automatic dose increase or abrupt discontinuation.
Urgent medical assessment is appropriate for:
The 2023 Medsafe Artane data sheet highlights the need to consider anticholinergic effects and individual risk factors when trihexyphenidyl is prescribed [2].
Trihexyphenidyl blocks some acetylcholine activity in the central nervous system. A neurotransmitter is a chemical messenger that carries signals between nerve cells or between nerves and muscles.
Parkinson’s disease involves reduced dopamine activity in movement pathways. This creates a relative imbalance between dopamine and acetylcholine signalling. Artane does not restore dopamine, but it can reduce some cholinergic signals that contribute to tremor and rigidity.
The action is not perfectly selective. Anticholinergic effects can also affect the salivary glands, eyes, bowel, bladder, sweating, and memory. This explains why symptom improvement and adverse effects may appear together. The FDA prescribing information describes this balance as a central consideration in trihexyphenidyl treatment [1].
By reducing excessive cholinergic signalling, Artane may make some movements easier and decrease muscle stiffness or tremor. Response varies between individuals and between symptoms.
A useful practical distinction is that tremor may respond more noticeably than balance, slowed thinking, or postural instability. Increasing the dose does not guarantee better walking or coordination, while it can increase confusion, falls, and blurred vision.
A common mistake is overlooking the combined effect of several medicines. A person may take Artane alongside another medicine that also causes dry mouth, constipation, blurred vision, or drowsiness, without realising that the effects add together.
Other frequent mistakes include:
Trihexyphenidyl is one anticholinergic approach to selected movement symptoms. Other treatment categories may target dopamine pathways, reduce involuntary muscle activity through a different mechanism, or address the underlying neurological diagnosis.
| Treatment approach | Main pharmacological focus | Substitution status |
|---|---|---|
| Trihexyphenidyl tablets | Reduces central acetylcholine activity | Use only according to the individual prescription |
| Dopamine-directed treatment | Increases or modifies dopamine signalling | Not automatically interchangeable |
| Other anticholinergic treatment | Reduces acetylcholine activity through another medicine | Requires review because dose and adverse effects differ |
Medicines with similar therapeutic goals are not automatically equivalent. A different tablet may have another active ingredient, release pattern, interaction profile, or cognitive risk. Never substitute a movement-disorder medicine without prescriber or pharmacist approval.
Clinicians often weigh motor benefit against cognition, falls, constipation, urinary risk, and vision changes before continuing Artane. A small improvement in tremor may be worthwhile for one person and less useful for another if it comes with confusion or repeated falls.
Useful monitoring includes:
A family member or carer can provide valuable observations. Memory problems may be subtle at first, while a sudden fall or episode of confusion can be more obvious.
Take the missed tablet when remembered unless the next scheduled dose is near, then continue with the usual schedule. Do not double the next dose to compensate. The 2024 DailyMed trihexyphenidyl label describes individual dose adjustment as central to safe use; the correct action also depends on the prescribed timing plan [3].
Yes. Trihexyphenidyl can cause memory problems, confusion, reduced concentration, agitation, or hallucinations, with greater concern in older adults. A 2019 WHO technical report supports careful assessment of cognitive adverse effects when anticholinergic treatment is used [4]. New or worsening confusion should be reported promptly rather than managed by changing the dose independently.
The treatment duration depends on the diagnosis, symptom response, age, and adverse effects. Some people use trihexyphenidyl for longer periods, while others need a different strategy when cognitive, urinary, bowel, or falls risks increase. The 2019 FDA prescribing information supports regular review of continued treatment. Regular treatment review is appropriate because the balance between movement benefit and anticholinergic burden can change over time.
Some movement symptoms may change after treatment begins or after a dose adjustment, but the timing varies by the symptom being treated and the individual schedule. The 2019 FDA prescribing information supports evaluating both benefit and tolerability rather than relying on a fixed response time. Keep track of the specific symptom, such as tremor or stiffness, rather than judging the medicine only by general feelings.
Older adults may be more sensitive to confusion, memory problems, blurred vision, constipation, urinary retention, dizziness, and falls. The treatment may still be prescribed when the expected movement benefit justifies those risks, with close review of cognition and daily function. Medsafe’s 2023 Artane data sheet supports individual assessment rather than automatic use or automatic avoidance.
Alcohol may increase drowsiness, dizziness, impaired coordination, and difficulty concentrating while using Artane. The risk is more concerning when the person already has balance problems, takes other sedating medicines, or is adjusting the dose. The WHO’s 2019 medication-safety report supports avoiding combinations that increase impairment during activities requiring alertness.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Artane tablets are used in different strengths, including 2 mg and 5 mg presentations. The strength chosen reflects the prescribed titration plan, not a general ranking of treatment quality.
The lower strength may allow smaller dose adjustments, while the higher strength may be used when the prescriber considers a larger individual dose appropriate. Either strength can be unsuitable for a particular person.
| Tablet strength | Main prescribing role | Practical point |
|---|---|---|
| 2 mg | Smaller dose adjustments or titration | Useful when tolerability needs close assessment |
| 5 mg | Prescribed dose after individual review | Never assume it is appropriate because it contains more medicine |
Older age, memory problems, glaucoma risk, urinary symptoms, constipation, and other anticholinergic medicines can all influence strength selection. A person who previously tolerated Artane may tolerate it differently after illness, dehydration, a fall, or a change in other medicines.
My hand tremor was easier to manage during meals. Dry mouth was annoying at first, and I needed to pay more attention to fluids. The benefit was useful, but I did not increase the tablets on difficult days.
The stiffness improved gradually rather than after the first tablet. I had constipation and some blurred vision, so the prescriber reviewed my medicines. The symptoms settled after the plan was adjusted.
The involuntary movements became less disruptive after the dose was adjusted. I also felt sleepy and found it harder to concentrate in the afternoon. It helped, but I would not drive until I knew how I reacted.
